AVB Biotech is gearing up to take another significant step in the fight against the COVID-19 pandemic.

In 2020, AVB Biotech introduced the groundbreaking Quantum Signal Treatment for the first time globally, and it is now taking its second step in COVID-19 treatment. A 100% success rate was achieved in the clinical study initiated on Covid-19 in 2022. Given the global increase in COVID-19 cases and the emergence of new variants, AVB Biotech has decided to extend the COVID-19 clinical study. The study, which resumed on October 16, 2023, is expected to conclude by the end of the year.

Quantum Signal Treatment has previously demonstrated its remarkable effectiveness in scientific studies on both enveloped and non-enveloped viruses. In fact, in a clinical study involving domestic animals, it achieved a 95% treatment success rate in cases of Feline Infections Peritonitis (FIP), which is the most lethal type of viral infection caused by a coronavirus in cats.

Developed by AVB Biotech, Quantum Signal Treatment renders pathogens like viruses and bacteria ineffective by applying specially encoded signals to the body. These signal codes also trigger anti-aging activities and enable rapid regeneration of tissues and organs (For a detailed look at the scientific research conducted, please visit www.avbbio.com). Initially designed for the treatment of deadly and contagious viral infections, this treatment technology is not affected by the development of variants and is capable of physically destroying pathogens without displaying any side effects. Therefore, it holds significant importance in minimizing the pandemic risk.

Serkan TUNÇ, the CEO of AVB Biotech, commented on the matter: “The COVID-19 pandemic poses a significant threat worldwide, and we have a responsibility to find solutions to bring an end to this challenging period. The DrBiolyse device represents a promising technology, and this study aims to take a crucial step in saving lives and protecting communities.”

AVB Biotech aims to utilize the DrBiolyse device as a groundbreaking tool not only for COVID-19 but also for the treatment of other diseases caused by viruses and bacteria. This endeavor represents the convergence of science, technology, and innovation to overcome the pandemic.